Flinn, I. W., Jacobson, C., Nastoupil, L. J., Morschhauser, F., Davies, A. J., Buske, C., Corradini, P., Lopez-Guillermo, A., Reshef, R., Parameswaran, V., Sehgal, A., Tees, M., Lui, C., Xue, W., Beygi, S., Grechko, N., Bolsue, P., Giovanetti, A., To, C., & Nahas, M. (2023). P1107: ZUMA-22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL VERSUS STANDARD-OF-CARE THERAPY IN PATIENTS WITH RELAPSED OR REFRACTORY FOLLICULAR LYMPHOMA. HemaSphere, 7(S3), e6350662. https://doi.org/10.1097/01.hs9.0000971324.63506.62

Shadman, M., Manzoor, B. S., Sail, K., Tuncer, H. H., Allan, J. N., Ujjani, C., Emechebe, N., Kamalakar, R., Coombs, C. C., Leslie, L., Barr, P. M., Brown, J. R., Eyre, T. A., Rampotas, A., Schuh, A., Lamanna, N., Skarbnik, A., Roeker, L. E., Bannerji, R., … Mato, A. R. (2023). Treatment Discontinuation Patterns for Patients With Chronic Lymphocytic Leukemia in Real-World Settings: Results From a Multi-Center International Study. Clinical Lymphoma Myeloma and Leukemia, 23(7), 515–526. https://doi.org/10.1016/j.clml.2023.03.010

Allen, P. B., Lu, X., Chen, Q., O’Shea, K., Chmiel, J. S., Slonim, L. B., Sukhanova, M., Savas, H., Evens, A. M., Advani, R., Pro, B., Karmali, R., Palmer, B., Bayer, R. A., Eisner, R. M., Mou, E., Dillehay, G., Gordon, L. I., & Winter, J. N. (2023). Sequential pembrolizumab and AVD are highly effective at any PD-L1 expression level in untreated Hodgkin lymphoma. Blood Advances, 7(12), 2670–2676. https://doi.org/10.1182/bloodadvances.2022008116

Pal, I., Scotto, L., Sabzevari, A., Kinahan, C., Fox, T. E., Feith, D. J., Marchi, E., Loughran, T. P., & O’Connor, O. A. (2023). Identifying the mechanistic differences between hypomethylating agents for the treatment of peripheral T cell lymphoma. Hematological Oncology, 41(S2), 313–314. Portico. https://doi.org/10.1002/hon.3164_220

Kim, W. S., Shortt, J., Zinzani, P. L., Mikhaylova, N., Marin‐Niebla, A., Radeski, D., Ribrag, V., Domenech, E. D., Sawas, A., Alexis, K., Emig, M., Garcia, L., Overesch, A., Pietzko, K., & Horwitz, S. (2023). AFM13 IN PATIENTS WITH CD30 POSITIVE RELAPSED OR REFRACTORY (R/R) PERIPHERAL T CELL LYMPHOMA (PTCL): RESULTS FROM THE PHASE 2 REDIRECT STUDY. Hematological Oncology, 41(S2), 195–196. Portico. https://doi.org/10.1002/hon.3163_126

Mehta‐Shah, N., Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter‐Brown, L., Izutsu, K., Waters, S., Brammer, J. E., Pro, B., & Horwitz, S. M. (2023). Duvelisib in patients with relapsed/refractory peripheral T‐cell lymphoma from the phase 2 PRIMO Trial Expansion Phase: outcomes by baseline histology. Hematological Oncology, 41(S2), 499–500. Portico. https://doi.org/10.1002/hon.3164_367

Fahmy, L. M., Yang, H. R., Zhou, M., Beylergil, V., Schreidah, C. M., Kwinta, B. D., Schwartz, L. H., Fojo, A. T., Bates, S. E., & Geskin, L. J. (2023). LYMPH NODE AND SKIN SCORING GROWTH KINETICS PREDICT OUTCOMES IN CUTANEOUS T‐CELL LYMPHOMA: AN INTERIM ANALYSIS. Hematological Oncology, 41(S2), 772–772. Portico. https://doi.org/10.1002/hon.3165_619

Brown, J. R., Eichorst, B., Ghia, P., Jurczak, W., Kahl, B. S., Lamanna, N., Robak, T., Shadman, M., Tam, C. S., Qiu, L., Cohen, A., Zhang, M., Salmi, T., Paik, J., Wang, L., Zhang, J., Ma, H., & Tedeschi, A. (2023). Zanubrutinib safety/tolerability profile and comparison with ibrutinib profile in B‐cell malignancies: Post hoc analysis of a large clinical trial safety database. Hematological Oncology, 41(S2), 459–461. Portico. https://doi.org/10.1002/hon.3164_339

Amengual, J. E., Reagan, P., Li, H., Saeed, H., Vaidya, R., Unger, J. M., Danilov, A., LeBlanc, M., Friedberg, J. W., & Smith, S. M. (2023). S2207: RANDOMIZED PHASE II STUDY OF THE ADDITION OF TARGETED AGENTS TO TAFASITAMAB‐LENALIDOMIDE IN TRANSPLANT INELIGIBLE PATIENTS WITH RELAPSED/REFRACTORY LBCL. Hematological Oncology, 41(S2), 842–843. Portico. https://doi.org/10.1002/hon.3166_ot22

Tolu, S. S., Seshadri, M. R., Chen, Z., Orlando, E., Grenet, J., Toor, R., Sanjurjo, A., Phillips, A., Shore, T., Martin, P., Leonard, J. P., Pro, B., Amengual, J. E., & Ruan, J. (2023). Outcomes of contemporary novel agent incorporation in relapsed/refractory PTCL. Hematological Oncology, 41(S2), 511–512. Portico. https://doi.org/10.1002/hon.3164_377

Flinn, I. W., Jacobson, C. A., Nastoupil, L. J., Morschhauser, F., Davies, A., Buske, C., Corradini, P., Lopez‐Guillermo, A., Reshef, R., Parameswaran, V., Sehgal, A., Tees, M., Lui, C., Xue, W., Beygi, S., Grechko, N., Bolsue, P., Giovanetti, A., To, C., & Nahas, M. (2023). ZUMA‐22: A PHASE 3, RANDOMIZED CONTROLLED STUDY OF AXICABTAGENE CILOLEUCEL (AXI‐CEL) VS STANDARD‐OF‐CARE THERAPY IN PATIENTS WITH RELAPSED/REFRACTORY FOLLICULAR LYMPHOMA. Hematological Oncology, 41(S2), 853–855. Portico. https://doi.org/10.1002/hon.3166_ot31

Wang, M. L., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I., Tessoulin, B., Alencar, A. J., Ma, S., Lewis, D., Lech-Maranda, E., Rhodes, J., Patel, K., Maddocks, K., Lamanna, N., … Shah, N. N. (2023). Pirtobrutinib in Covalent Bruton Tyrosine Kinase Inhibitor Pretreated Mantle-Cell Lymphoma. Journal of Clinical Oncology, 41(24), 3988–3997. https://doi.org/10.1200/jco.23.00562

Kim, D.-W., Kim, S.-W., Camidge, D. R., Shu, C. A., Marrone, K. A., Le, X., Blakely, C. M., Park, K., Chang, G.-C., Patel, S. P., Kar, G., Cooper, Z. A., Samadani, R., Pluta, M., Kumar, R., & Ramalingam, S. (2023). CD73 Inhibitor Oleclumab Plus Osimertinib in Previously Treated Patients With Advanced T790M-Negative EGFR-Mutated NSCLC: A Brief Report. Journal of Thoracic Oncology, 18(5), 650–656. https://doi.org/10.1016/j.jtho.2022.12.021

Belsky, J. A., Shoag, J., Harker-Murray, P. D., & Kahn, J. M. (2023). Advances in Pediatric Hodgkin Lymphoma with an Eye on Disparities and Vulnerable Populations. Advances in Oncology, 3(1), 67–76. https://doi.org/10.1016/j.yao.2023.01.016

Cherng, H.-J. J., Alig, S. K., Oki, Y., Nastoupil, L. J., Fayad, L., Neelapu, S. S., Turturro, F., Hagemeister, F., Craig, A. F. M., Macaulay, C. W., Rodriguez, M. A., Lee, H. J., McDonnell, T. J., Flowers, C. R., Vega, F., Green, M. R., Feng, L., Kurtz, D. M., Alizadeh, A. A., … Westin, J. R. (2023). A phase 1/2 study of lenalidomide and obinutuzumab with CHOP for newly diagnosed DLBCL. Blood Advances, 7(7), 1137–1145. https://doi.org/10.1182/bloodadvances.2022008174

Brown, J. R., Eichhorst, B., Hillmen, P., Jurczak, W., Kaźmierczak, M., Lamanna, N., O’Brien, S. M., Tam, C. S., Qiu, L., Zhou, K., Simkovic, M., Mayer, J., Gillespie-Twardy, A., Ferrajoli, A., Ganly, P. S., Weinkove, R., Grosicki, S., Mital, A., Robak, T., … Shadman, M. (2023). Zanubrutinib or Ibrutinib in Relapsed or Refractory Chronic Lymphocytic Leukemia. New England Journal of Medicine, 388(4), 319–332. https://doi.org/10.1056/nejmoa2211582

Mucha, B., Qie, S., Bajpai, S., Tarallo, V., Diehl, J. N., Tedeschi, F., Zhou, G., Gao, Z., Flashner, S., Klein-Szanto, A. J., Hibshoosh, H., Masataka, S., Chajewski, O. S., Majsterek, I., Pytel, D., Hatzoglou, M., Der, C. J., Nakagawa, H., Bass, A. J., … Diehl, J. A. (2022). Tumor suppressor mediated ubiquitylation of hnRNPK is a barrier to oncogenic translation. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-34402-6

de Leval, L., Alizadeh, A. A., Bergsagel, P. L., Campo, E., Davies, A., Dogan, A., Fitzgibbon, J., Horwitz, S. M., Melnick, A. M., Morice, W. G., Morin, R. D., Nadel, B., Pileri, S. A., Rosenquist, R., Rossi, D., Salaverria, I., Steidl, C., Treon, S. P., Zelenetz, A. D., … Scott, D. W. (2022). Genomic profiling for clinical decision making in lymphoid neoplasms. Blood, 140(21), 2193–2227. https://doi.org/10.1182/blood.2022015854

Lee, H. J., Choi, M. Y., Siddiqi, T., Rhodes, J. M., Wierda, W. G., Isufi, I., Tuscano, J. M., Lamanna, N., Subbiah, S., Koff, J. L., Leslie, L., Goldenberg, A., Chung, G. G., Breitmeyer, J. B., Yazji, S., Wang, M., Jamieson, C., & Kipps, T. J. (2022). Phase 1/2 Study of Zilovertamab and Ibrutinib in Mantle Cell Lymphoma (MCL), Chronic Lymphocytic Leukemia (CLL), or Marginal Zone Lymphoma (MZL). Blood, 140(Supplement 1), 566–568. https://doi.org/10.1182/blood-2022-167153

Esplin, I., Huang, Y., Bhat, S. A., Grantier, C., Grever, M. R., Hoffman, C., Kittai, A. S., Lucas, M. S., Moran, M. E., Reid, M., Suresh, S., Woyach, J. A., & Rogers, K. A. (2022). Treatment of CLL-Associated Autoimmune Cytopenias and Outcomes in a Single Institution Cohort Study. Blood, 140(Supplement 1), 4166–4168. https://doi.org/10.1182/blood-2022-167314

Wang, M. L., Shah, N. N., Jurczak, W., Zinzani, P. L., Eyre, T. A., Cheah, C. Y., Ujjani, C. S., Koh, Y., Izutsu, K., Gerson, J. N., Flinn, I. W., Tessoulin, B., Alencar, A. J., Ma, S., Lech-Marańda, E., Rhodes, J. M., Patel, K., Woyach, J. A., Lamanna, N., … Mato, A. R. (2022). Efficacy of Pirtobrutinib in Covalent BTK-Inhibitor Pre-Treated Relapsed / Refractory Mantle Cell Lymphoma: Additional Patients and Extended Follow-up from the Phase 1/2 BRUIN Study. Blood, 140(Supplement 1), 9368–9372. https://doi.org/10.1182/blood-2022-159425

Mahadeo, K. M., Baiocchi, R. A., Beitinjaneh, A., Chaganti, S., Choquet, S., Dierickx, D., Dinavahi, R., Gamelin, L., Ghobadi, A., Guzman-Becerra, N., Joshi, M., Mehta, A., Nikiforow, S., Reshef, R., Ye, W., & Prockop, S. (2022). New and Updated Results from a Multicenter, Open-Label, Global Phase 3 Study of Tabelecleucel (Tab-cel) for Epstein-Barr Virus-Positive Post-Transplant Lymphoproliferative Disease (EBV+ PTLD) Following Allogeneic Hematopoietic Cell (HCT) or Solid Organ Transplant (SOT) after Failure of Rituximab or Rituximab and Chemotherapy (ALLELE). Blood, 140(Supplement 1), 10374–10376. https://doi.org/10.1182/blood-2022-157766

Stiefel, J., Flower, A. M., Botwinick, M., Ford, M., Foti, A., Gandhi, M., Slovin, J., Smilow, E., Bowers, A., Karpel, H., Schwartz, L. Y., Fraint, E., Gennarini, L. M., Gardner, S. L., Raetz, E. A., Shah, N. C., Chen, J., Krajewski, J., Hijiya, N., … Sulis, M. L. (2022). Antigen Directed Therapy Pre-Transplant Confers Superior Post-Transplant Survival Outcome Compared to Conventional Chemotherapy in Pediatric Patients with Relapsed and Refractory B-ALL. Blood, 140(Supplement 1), 7763–7765. https://doi.org/10.1182/blood-2022-160272

Chapman-Fredricks, J. R., Thakkar, D., Alderuccio, J. P., Naresh, K. N., Ondrejka, S. L., Hsi, E. D., Xu, M. L., Paulson, N., Koff, J. L., Jaye, D. L., Cohen, J. B., Ortved Gang, A., Leeman-Neill, R. J., Dave, T., Happ, L., Love, C., Zandi, S., Naushad, H., Mason, E. F., … Lossos, I. S. (2022). Extranodal Marginal Zone Lymphomas Show Recurrent Mutations in DNA Repair Genes, Cancer-Associated Proliferative Signaling and NOTCH1 Signaling Pathways, Regardless of Anatomic Site. Blood, 140(Supplement 1), 6378–6380. https://doi.org/10.1182/blood-2022-165616

Koff, J. L., Kositsky, R., Jaye, D. L., Churnetski, M. C., Baird, K., O’Leary, C. B., Flowers, C. R., Leppa, S., Karjalainen-Lindsberg, M.-L., Li, S., Xu, J., Pedersen, M. Ø., Gang, A. O., Naresh, K. N., Leeman-Neill, R. J., Au Yeung, K. H. R., Qureishi, H. N., Iqbal, J., Chapman-Fredricks, J. R., … Cohen, J. B. (2022). Mutations of ATM Confer a Risk of Inferior Survival in Patients with TP53-wild Type Mantle Cell Lymphoma. Blood, 140(Supplement 1), 3500–3503. https://doi.org/10.1182/blood-2022-168002

Fahmy, L., Yang, H. R., Kwinta, B., Beylergil, V., Schreidah, C. M., Schwartz, L. H., & Geskin, L. J. (2022). Evaluation of Volumetric Lymph Node Measurements in Cutaneous T-Cell Lymphoma Patients Enrolled in the Mavoric Trial: An Interim Analysis. Blood, 140(Supplement 1), 3700–3700. https://doi.org/10.1182/blood-2022-163711

Schroers-Martin, J., Garofalo, A., Soo, J., Boegeholz, J., Alig, S. K., Sworder, B., Liu, C. L., Luikart, H., Gamino, G., Morales, D., Freystätter, K., Hamilton, J., Kurtz, D. M., Hollander, S., Rosenthal, D., Dhillon, G., Raikhelkar, J., Verleden, S., Nijland, M., … Alizadeh, A. A. (2022). Tumor Microenvironment Determinants of Immunotherapy Response Identified By Integrated Host & Viral Analysis of Post-Transplant Lymphoproliferative Disorders. Blood, 140(Supplement 1), 172–174. https://doi.org/10.1182/blood-2022-158647

Jacobsen, E. D., Zinzani, P. L., Zain, J., Mead, M., Casulo, C., Gritti, G., Pinter-Brown, L. C., Izutsu, K., Daugherty, M., Brammer, J. E., Mehta-Shah, N., Pro, B., & Horwitz, S. M. (2022). Duvelisib in Patients with Relapsed/Refractory Peripheral T-Cell Lymphoma from the Phase 2 Primo Trial Expansion Phase: Impact of Prior Treatment and Expanded Safety Analysis. Blood, 140(Supplement 1), 9387–9389. https://doi.org/10.1182/blood-2022-169432

Batlevi, C. L., Salles, G., Park, S. I., Phillips, T. J., Amengual, J. E., Andorsky, D., Campbell, P., McKay, P., Leonard, J. P., Sondhi, M., Chen, Y., Slatcher, P. L., Lin, R., Szanto, A., Abbadi, S., & Morschhauser, F. (2022). Tazemetostat in Combination with Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma: Phase 1b Results of Symphony-1. Blood, 140(Supplement 1), 2296–2298. https://doi.org/10.1182/blood-2022-166991

Lue, J. K., Stevens, D. A., Williams, M. E., Westin, J., Ewesuedo, R., McDonald, A., Agarwal, S., Henrick, P., Perea, R., & Gollob, J. (2022). Phase 1 Study of KT-413, a Targeted Protein Degrader of IRAK4 and IMiD Substrates, in Adult Patients with Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma. Blood, 140(Supplement 1), 12143–12144. https://doi.org/10.1182/blood-2022-170151

Melody, M., St. Pierre, F., Helenowski, I., Pearse, W. B., Vakkalagadda, C. V., Leventhal, J. R., Friedewald, J., Ho, B., Ganger, D., Winter, J. N., Gordon, L. I., Lin, A. Y., Karmali, R., Ma, S., Pro, B., & Moreira, J. (2022). Impact of Extranodal Disease Involvement on Outcomes in Post-Transplant Lymphoproliferative Disorder. Blood, 140(Supplement 1), 6674–6675. https://doi.org/10.1182/blood-2022-164724

Savage, K. J., Horwitz, S. M., Advani, R., Christensen, J. H., Domingo-Domenech, E., Rossi, G., Morschhauser, F., Alpdogan, O., Suh, C., Tobinai, K., Shustov, A., Trneny, M., Yuen, S., Zinzani, P. L., Trümper, L., Ilidge, T., O’Connor, O. A., Pro, B., Miao, H., … Iyer, S. (2022). Role of stem cell transplant in CD30+ PTCL following frontline brentuximab vedotin plus CHP or CHOP in ECHELON-2. Blood Advances, 6(19), 5550–5555. https://doi.org/10.1182/bloodadvances.2020003971

Flerlage, J. E., Birz, S., Castellino, S. M., Appel, B., Furner, B., Graglia, L., Henderson, T. O., Hodgson, D., Hoppe, B. S., Kahn, J., Keller, F. G., Kessel, S., Li, C., Li, M., Lucas, J., Mccarten, K., Metzger, M., Milgrom, S., Parsons, S. K., … Kelly, K. M. (2022). P086: Advancing Pediatric Hodgkin Lymphoma Research Through NODAL. HemaSphere, 6, 39–40. https://doi.org/10.1097/01.hs9.0000890912.56229.80

Ingham, M., Blay, J.-Y., Baird, J., D’Silva, D., O’Keefe, K., Kong, R., Spiegel, R., Wahba, M., & Weetall, M. (2022). 1528TiP A phase II/III study evaluating the efficacy and safety of unesbulin in advanced leiomyosarcoma (SUNRISELMS). Annals of Oncology, 33, S1243–S1244. https://doi.org/10.1016/j.annonc.2022.07.1917

Olsen, E. A., Whittaker, S., Willemze, R., Pinter-Brown, L., Foss, F., Geskin, L., Schwartz, L., Horwitz, S., Guitart, J., Zic, J., Kim, Y. H., Wood, G. S., Duvic, M., Ai, W., Girardi, M., Gru, A., Guenova, E., Hodak, E., Hoppe, R., … Scarisbrick, J. (2022). Primary cutaneous lymphoma: recommendations for clinical trial design and staging update from the ISCL, USCLC, and EORTC. Blood, 140(5), 419–437. https://doi.org/10.1182/blood.2021012057

Gaydosik, A. M., Stonesifer, C. J., Khaleel, A. E., Geskin, L. J., & Fuschiotti, P. (2022). Single-Cell RNA Sequencing Unveils the Clonal and Transcriptional Landscape of Cutaneous T-Cell Lymphomas. Clinical Cancer Research, 28(12), 2610–2622. https://doi.org/10.1158/1078-0432.ccr-21-4437

Gounder, M. M., Agaram, N. P., Trabucco, S. E., Robinson, V., Ferraro, R. A., Millis, S. Z., Krishnan, A., Lee, J., Attia, S., Abida, W., Drilon, A., Chi, P., Angelo, S. P. D., Dickson, M. A., Keohan, M. L., Kelly, C. M., Agulnik, M., Chawla, S. P., Choy, E., … Jin, D. X. (2022). Clinical genomic profiling in the management of patients with soft tissue and bone sarcoma. Nature Communications, 13(1). https://doi.org/10.1038/s41467-022-30496-0

Mato, A. R., Pagel, J. M., Coombs, C. C., Shah, N. N., Lamanna, N., Munir, T., Lech-Maranda, E., Eyre, T. A., Woyach, J. A., Wierda, W. G., Cheah, C. Y., Cohen, J. B., Roeker, L. E., Patel, M. R., Fakhri, B., Barve, M. A., Tam, C., Lewis, D., Gerson, J. N., … Jurczak, W. (2022). S147: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED CLL/SLL: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. HemaSphere, 6, 48–49. https://doi.org/10.1097/01.hs9.0000843480.04890.cc

Eyre, T. A., Wang, M. L., Shah, N. N., Alencar, A. J., Gerson, J. N., Patel, M. R., Fakhri, B., Vandenberghe, E., Jurczak, W., Tan, X. N., Lewis, K. L., Fenske, T., Wang, Y., Coombs, C. C., Flinn, I., Lewis, D., Le Gouill, S., Gandhi, M., Chay, C., … Cheah, C. Y. (2022). P1101: PIRTOBRUTINIB, A HIGHLY SELECTIVE, NON-COVALENT (REVERSIBLE) BTK INHIBITOR IN PREVIOUSLY TREATED MANTLE CELL LYMPHOMA: UPDATED RESULTS FROM THE PHASE 1/2 BRUIN STUDY. HemaSphere, 6, 991–992. https://doi.org/10.1097/01.hs9.0000847272.47630.ff

Petri, M. A., Bertsias, G., Daniels, M., Fox, N. L., Hahn, B. H., Hammer, A., Harris, J., Quasny, H., Tani, C., & Askanase, A. (2022). POS0183 THE EFFECT OF BELIMUMAB ON SRI-4 RESPONSE IN MULTIPLE SUBGROUPS OF PATIENTS WITH SYSTEMIC LUPUS ERYTHEMATOSUS: RESULTS OF A LARGE INTEGRATED ANALYSIS. Annals of the Rheumatic Diseases, 81, 323. https://doi.org/10.1136/annrheumdis-2022-eular.1807

Soderquist, C. R., & Bhagat, G. (2022). Indolent T- and NK-Cell Lymphoproliferative Disorders of the Gastrointestinal Tract: Current Understanding and Outstanding Questions. Hemato, 3(1), 219–231. https://doi.org/10.3390/hemato3010018

Mato, A. R., Davids, M. S., Sharman, J., Roeker, L. E., Kay, N., Kater, A. P., Rogers, K., Thompson, M. C., Rhodes, J., Goy, A., Skarbnik, A., Schuster, S. J., Tam, C. S., Eyre, T. A., O’Brien, S., Nabhan, C., Lamanna, N., Sun, C., Shadman, M., … Woyach, J. A. (2021). Recognizing Unmet Need in the Era of Targeted Therapy for CLL/SLL: “What’s Past Is Prologue” (Shakespeare). Clinical Cancer Research, 28(4), 603–608. https://doi.org/10.1158/1078-0432.ccr-21-1237

Albitar, M., Zhang, H., Goy, A., Xu-Monette, Z. Y., Bhagat, G., Visco, C., Tzankov, A., Fang, X., Zhu, F., Dybkaer, K., Chiu, A., Tam, W., Zu, Y., Hsi, E. D., Hagemeister, F. B., Huh, J., Ponzoni, M., Ferreri, A. J. M., Møller, M. B., … Young, K. H. (2022). Determining clinical course of diffuse large B-cell lymphoma using targeted transcriptome and machine learning algorithms. Blood Cancer Journal, 12(2). https://doi.org/10.1038/s41408-022-00617-5

Houot, R., Poeschel, V., Altmann, B., Angel, S., Thurner, L., Illmer, T., Andre, M., Dreyling, M., Maisonneuve, H., Tilly, H., Mayer, S., Casasnovas, O., Le Gouill, S., Offner, F., Cartron, G., Kerkhoff, A., Weber, T., Hoffmann, J., Ziepert, M., … Held, G. (2022). Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. HemaSphere, 6(2), e672. https://doi.org/10.1097/hs9.0000000000000672

Gibson, S. E., Liu, Y.-C., Yatsenko, S. A., Barasch, N. J., & Swerdlow, S. H. (2022). Histopathologic, immunophenotypic, and mutational landscape of follicular lymphomas with plasmacytic differentiation. Modern Pathology, 35(1), 60–68. https://doi.org/10.1038/s41379-021-00938-z

Di Napoli, A., Vacca, D., Bertolazzi, G., Lopez, G., Piane, M., Germani, A., Rogges, E., Pepe, G., Santanelli Di Pompeo, F., Salgarello, M., Jobanputra, V., Hsiao, S., Wrzeszczynski, K. O., Berti, E., & Bhagat, G. (2021). RNA Sequencing of Primary Cutaneous and Breast-Implant Associated Anaplastic Large Cell Lymphomas Reveals Infrequent Fusion Transcripts and Upregulation of PI3K/AKT Signaling via Neurotrophin Pathway Genes. Cancers, 13(24), 6174. https://doi.org/10.3390/cancers13246174

Kahn, J. M., Maguire, F. B., Li, Q., Abrahão, R., Flerlage, J. E., Alvarez, E., & Keegan, T. H. M. (2021). Initial cancer treatment and survival in children, adolescents, and young adults with Hodgkin lymphoma: A population‐based study. Cancer, 127(24), 4613–4619. Portico. https://doi.org/10.1002/cncr.33868

Leeman-Neill, R. J., Thakkar, D., Ondrejka, S. L., Hsi, E. D., Chadburn, A., Mejia Saldarriaga, M., Rutherford, S. C., McCall, C. M., Aljurf, T., McKinney, M., Koff, J. L., Jaye, D. L., Cohen, J. B., Soliman, D. S., Louissaint, A., Ong, C. K., Cheng, C. L., Lee, L., Behdad, A., … Bhagat, G. (2021). Genomic and Transcriptional Characterization of Primary Mediastinal Large B Cell Lymphoma. Blood, 138(Supplement 1), 2398–2398. https://doi.org/10.1182/blood-2021-149745

Batlevi, C. L., Park, S. I., Nastoupil, L., Phillips, T., Amengual, J. E., Andorsky, D., Campbell, P., McKay, P., Pagel, J. M., Leonard, J. P., Yang, J., O’Connor, H., Hamlett, A., Adib, D., & Morschhauser, F. (2021). Interim Analysis of the Randomized Phase 1b/3 Study Evaluating the Safety and Efficacy of Tazemetostat Plus Lenalidomide and Rituximab in Patients with Relapsed/Refractory Follicular Lymphoma. Blood, 138(Supplement 1), 2207–2207. https://doi.org/10.1182/blood-2021-148199

Au Yeung, K. H. R., Russell, V., Choi, W., Wong, A., Tsui, L., Lee, Y. Y. C., Li, J., Gill, H., Ip, H.-W., Kwong, Y. L., Dave, T., Ondrejka, S. L., Bhagat, G., Chadburn, A., Rutherford, S. C., Koff, J. L., Jaye, D. L., Czader, M., Louissaint, A., … Tse, E. (2021). ALK-Negative Anaplastic Large Cell Lymphomas Encompass Distinct Subgroups Including an ALK-Positive-like Subgroup with Favorable Prognosis. Blood, 138(Supplement 1), 2403–2403. https://doi.org/10.1182/blood-2021-148807